Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to ...

Pharmaceutical giant Pfizer (NYSE: PFE) is trading near its lowest price in over a decade. The company's revenue and profits ballooned during the pandemic on its COVID-19 vaccine and treatment ...

Its financials aren't in bad shape, and while the stock has been struggling, now could mak 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 | Nasdaq Skip to main content ...

Today's Best Finance Deals The Latest On Pfizer On Feb. 4, the company announced its Q4 2024 earnings, posting adjusted EPS of $0.63, beating the consensus estimate of $0.47, as reported by Benzinga .

In 2025, PFE stock is down 8%, compared to SPX’s 5.3% fall on a YTD basis. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?